Opinion|Videos|September 6, 2024
Addressing Unmet Needs and Emerging Agents
Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Despite the available treatment options, what are the remaining unmet needs or areas requiring further research and development in the management of disease states driven by type 2 inflammation?
- What emerging agents in the pipeline are you most excited for?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS
5